BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 16, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 11/13 cls
Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) BMO Capital Markets Robert Hazlett Price target Market perform 10% $9.88
Hazlett raised his target to $10 from $8 after Enzon announced the sale of its specialty pharmaceuticals business to Sigma-Tau S.p.A. for $300M in cash, up to $27M in potential milestones and 5-10% royalties (see B5). He thinks this will allow the company to focus on its early stage pipeline, including PEG-SN38. The pegylated form of SN38, the active metabolite...

Read the full 578 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >